BioStock: PHI’s CEO comments on the approved US listing

August 21, 2024
Language flag

Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.

Read the full interview with Patrik Eschricht on biostock.se.

The dual listing on the OTCQB market represents a significant step in
making PHI’s shares more accessible to US investors. This listing
increases our visibility in the US, aligning with our strategic focus on
expanding into the regenerative medicine market.

Further reading

Biostock interview with CEO Peter Egelberg
1…678

Latest News

Interview-John-More-website

Interview with John Moore

Meet John Moore, the proposed new board member for PHI. John’s extensive experience and visionary mindset make him an invaluable addition to our team. Let’s dive into his journey and what made him interested in PHI.

Notice of extraordinary general meeting in Phase Holographic Imaging PHI AB 19 August 2024

Phase Holographic Imaging PHI AB (publ), reg. no. 556542-7811 (the “Company”), will hold an extraordinary general meeting on 19 August at 14:00 at the Company’s premises at Skiffervägen 48 in Lund.

Board member Leland Foster resigns due to personal reasons

PHI announces the resignation of esteemed board member Leland Foster. Mr. Foster has decided to resign from his position due to his age and his desire to retire from professional commitments. After this, the Board of Directors continues to have a quorum in accordance with the Articles of Association.
See All News